Antimicrobial Activity of the Iron-Chelator, DIBI, against Multidrug-Resistant Canine Methicillin-Susceptible Staphylococcus pseudintermedius: A Preliminary Study of Four Clinical Strains
- PMID: 35745511
- PMCID: PMC9227175
- DOI: 10.3390/pathogens11060656
Antimicrobial Activity of the Iron-Chelator, DIBI, against Multidrug-Resistant Canine Methicillin-Susceptible Staphylococcus pseudintermedius: A Preliminary Study of Four Clinical Strains
Abstract
Staphylococcus pseudintermedius is an important opportunistic pathogen causing various infections in dogs. Furthermore, it is an emerging zoonotic agent and both multidrug-resistant methicillin-resistant S. pseudintermedius (MRSP) as well as methicillin-susceptible (MSSP) strains represent an important therapeutic challenge to veterinary medicine and pose a potential threat to human health. We tested representative S. pseudintermedius clinical strains from dogs suffering from otitis externa for their susceptibilities to a panel of 17 antimicrobials compared to DIBI. DIBI, unlike antibiotics, is a novel water-soluble hydroxypyridinone-containing iron-chelating agent that deprives microbes of growth-essential iron and has been previously shown to inhibit methicillin-resistant Staphylococcus aureus (MRSA). We also characterised the strains according to whether they harbour key antibiotic resistance genes. The strains each displayed multiple antimicrobial resistance patterns; all were negative for the mecA gene and possessed the tetK and tetM genes, but they varied as to their possession of the ermB gene. However, all the isolates had similar susceptibility to DIBI with low MICs (2 µg/mL or 0.2 µM). Because the four MSSPs were equally susceptible to DIBI, subject to confirmation with additional strains, this could provide a potential non-antibiotic, anti-infective alternative approach for the treatment of antimicrobial-resistant canine S. pseudintermedius otitis.
Keywords: DIBI; Staphylococcus pseudintermedius; antimicrobial resistance; iron chelator.
Conflict of interest statement
B.E.H. has a beneficial interest in Fe Pharmaceuticals (Canada) Inc. The other authors declare no conflicts of interest.
Figures
References
-
- De Martino L., Nocera F.P., Mallardo K., Nizza S., Masturzo E., Fiorito F., Iovane G., Catalanotti P. An update on microbiological causes of canine otitis externa in Campania Region, Italy. Asian Pac. J. Trop. Biomed. 2016;6:384–389. doi: 10.1016/j.apjtb.2015.11.012. - DOI
-
- Menandro M.L., Dotto G., Mondin A., Martini M., Ceglie L., Pasotto D. Prevalence and characterization of methicillin-resistant Staphylococcus pseudintermedius from symptomatic companion animals in Northern Italy: Clonal diversity and novel sequence types. Comp. Immunol. Microbiol. Infect. Dis. 2019;66:101331. doi: 10.1016/j.cimid.2019.101331. - DOI - PubMed
-
- Lord J., Millis N., Duckett Jones R., Johnson B., Kania S.A., Odoi A. Patterns of antimicrobial, multidrug and methicillin resistance among Staphylococcus spp. isolated from canine specimens submitted to a diagnostic laboratory in Tennessee, USA: A descriptive study. BMC Vet. Res. 2022;18:91. doi: 10.1186/s12917-022-03185-9. - DOI - PMC - PubMed
-
- Nocera F.P., Meroni G., Fiorito F., De Martino L., Martino P.A. Occurrence and antimicrobial susceptibility patterns of canine Staphylococcus pseudintermedius strains isolated from two different Italian university veterinary hospitals. Vet. Ital. 2020;56:263–269. doi: 10.12834/VetIt.2195.12897.1. - DOI - PubMed
LinkOut - more resources
Full Text Sources
